Selective thyromimetic drugs that reduce liver fat are showing promise as the first potential pharmacological agents to treat patients with nonalcoholic steatohepatitis (NASH), research in the Lancet shows. Patients with NASH had significant declines in hepatic fat compared with a placebo group after 12 weeks of taking a selective, liver-directed thyroid beta receptor agonist, according ...
New class of thyromimetics reduce liver fat to improve NASH
By Sunalie Silva
21 Nov 2019